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Background: Mitochondrial impairment has been implicated in the pathogenesis of Huntington’s disease (HD).
However, how mutant huntingtin impairs mitochondrial function and thus contributes to HD has not been fully
elucidated. In this study, we used striatal cells expressing wild type (STHdhQ7/Q7) or mutant (STHdhQ111/Q111)
huntingtin protein, and cortical neurons expressing the exon 1 of the huntingtin protein with physiological or
pathological polyglutamine domains, to examine the interrelationship among specific mitochondrial functions.
Results: Depolarization induced by KCl resulted in similar changes in calcium levels without compromising
mitochondrial function, both in wild type and mutant cells. However, treatment of mutant cells with thapsigargin
(a SERCA antagonist that raises cytosolic calcium levels), resulted in a pronounced decrease in mitochondrial
calcium uptake, increased production of reactive oxygen species (ROS), mitochondrial depolarization and
fragmentation, and cell viability loss. The mitochondrial dysfunction in mutant cells was also observed in cortical
neurons expressing exon 1 of the huntingtin protein with 104 Gln residues (Q104-GFP) when they were exposed to
calcium stress. In addition, calcium overload induced opening of the mitochondrial permeability transition pore
(mPTP) in mutant striatal cells. The mitochondrial impairment observed in mutant cells and cortical neurons
expressing Q104-GFP was prevented by pre-treatment with cyclosporine A (CsA) but not by FK506 (an inhibitor of
calcineurin), indicating a potential role for mPTP opening in the mitochondrial dysfunction induced by calcium
stress in mutant huntingtin cells.
Conclusions: Expression of mutant huntingtin alters mitochondrial and cell viability through mPTP opening in
striatal cells and cortical neurons.
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transition pore, Striatal cells, Mitochondrial fragmentationBackground
Huntington disease (HD) is a neurodegenerative disease
caused by the pathological elongation of the CAG re-
peats in exon 1 of the huntingtin protein gene [1]. HD is
characterized by dysfunction and loss of striatal neurons
in the initial stages, subsequently involving the cortex
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reproduction in any medium, provided the orExpression of mutant huntingtin can result in transcrip-
tional deregulation [3], and proteasome dysfunction in
brain cells [4-6]. More importantly, calcium deregulation
[7,8], and mitochondrial dysfunction [9-11] have been
strongly implicated in the pathogenesis of HD.
Regarding mitochondrial dysfunction, previous studies
have shown impairment of mitochondrial complex acti-
vities, which were specifically observed in the striatum
of HD patients [12,13]. Studies in primary neurons from
yeast artificial chromosome 128 (YAC128) mice, a trans-
genic mouse model of HD that expresses the full-length
human HD gene with several CAG repeats [14], indi-
cated that robust NMDAR activation produced mito-
chondrial dysfunction and inability to regulate cytosolictral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Quintanilla et al. Molecular Neurodegeneration 2013, 8:45 Page 2 of 19
http://www.molecularneurodegeneration.com/content/8/1/45calcium homeostasis in medium-sized spiny neurons
(MSNs) [15]. In addition, functional experiments, using
immortalized striatal cell lines (STHdh cells) and primary
striatal neurons from YAC128 HD mice expressing mu-
tant huntingtin, revealed impairments in mitochondrial
calcium handling [16]. More importantly, previous studies
showed that mutant huntingtin expression impaired mito-
chondrial ATP production [17], increased sensitivity of
mitochondria to calcium-induced respiratory defects [18],
and induced mitochondrial damage [19]. Studies in
isolated mitochondria showed that mitochondrial dysfunc-
tion induced by calcium stress can be prevented by cyclo-
sporine A (CsA), a blocker of mitochondrial permeability
transition pore (mPTP) induction [18,20], with immu-
nosuppressant effect [18]. Altogether these are important
observations but the use of isolated mitochondria limits
their physiological relevance. Therefore, new studies of
mitochondrial function in intact striatal cells that express
mutant huntingtin are needed to move forward in our
understanding of the pathogenesis of HD.
Interestingly, there is data suggesting that mutant hun-
tingtin impairs mitochondrial morphology and trafficking
[21-24]. Overexpression of huntingtin proteins containing
polyglutamine repeats in the pathological range, but not
those in the non-pathological range, increases oxidative
stress-induced mitochondrial fragmentation in HeLa cells
[22]. In STHdhQ111/Q111 cells and in lymphoblasts from
HD patients, significant mitochondrial fragmentation was
observed with cristae alterations that were aggravated by
stimulation of apoptosis [25]. Interestingly, a recent study
showed evidence of mitochondrial fragmentation with
increased expression of dynamin-related protein 1 (Drp1)
and mitochondrial fission protein 1 (Fis1), which control
mitochondrial fission in cerebral cortical samples from
HD patients [26]. However, the effects of calcium stress
on mitochondrial fragmentation in mutant huntingtin
cells needs to be examined.
In this work to study the mechanisms by which mutant
huntingtin affects mitochondrial function (calcium homeo-
stasis, reactive oxygen species (ROS) production, and
morphology) in response to calcium stress in a cellular con-
tex, we used cell lines obtained from wild type (HdhQ7/Q7)
and mutant huntingtin knock-in (HdhQ111/Q111) mice [27]
and rat cortical neurons. We examined cytosolic and
mitochondria calcium homeostasis, mitochondrial func-
tion, and mitochondrial morphology in striatal cells that
expressed wild type (STHdhQ7/Q7) and mutant huntingtin
(STHdhQ111/Q111). Cells were treated with different
stressors that increased cytosolic calcium concentration
by different mechanisms. Depolarization by KCl increased
cytosolic and mitochondrial calcium levels with no appar-
ent differences between wild type and mutant cells. In
wild type and mutant cells treatment with thapsigargin
induced a two-fold increase in cytosolic calcium levelscompared with KCl. However, in cells expressing mutant
huntingtin, thapsigargin-induced increase in cytosolic
calcium affected mitochondrial health, resulting membrane
potential loss, oxidative stress, and mitochondrial fragmen-
tation. More importantly, these changes were prevented by
pre-treatment with cyclosporine A (CsA) but no by FK-
506, an inhibitor of calcineurin (a calcium dependent phos-
phatase). In addition, thapsigargin induced the opening of
mPTP in mutant huntingtin cells. Expression of a mutant
huntingtin construct in cortical neurons also resulted in
calcium stress-induced loss of mitochondrial membrane
potential, which was also prevented by CsA.
Results
Effect of depolarization on calcium regulation in mutant
huntingtin cells
It has been suggested that mutant huntingtin induces
calcium-handling defects in neuronal cells exposed to
various stressors [28]. However, it is unclear which me-
chanisms are involved in this deregulation. Therefore,
we evaluated the cytosolic and mitochondrial calcium
changes in clonal striatal cells expressing mutant hun-
tingtin protein in response to depolarization and calcium
overload. Interestingly, immunofluorescence studies of
striatal cells stained with an anti-huntingtin antibody and
mitochondrial markers (Mitotracker® Red CM-H2XRos
(MitoRed) and cytochrome C) showed an evident coloca-
lization, indicating that huntingtin and mitochondria are
associated (Additional file 1: Figure S1). To evaluate cal-
cium changes in response to depolarization, wild type and
mutant striatal cells were treated with 60 mM KCl, which
results in a transient intra-neuronal calcium increase [29].
Cytosolic and mitochondrial calcium levels were simulta-
neously monitored using Fluo-3AM and Rhod-2AM,
respectively [19]. As expected, KCl-induced depolarization
produced a transient increase in cytosolic and mito-
chondrial calcium levels that was similar in both cell types
(Figure 1A, C). Thapsigargin was used to evaluate the
effects of pathological cytosolic calcium increases on
mitochondrial function. This compound inhibits calcium
uptake by endoplasmic reticulum and thus results in an
abnormaly high increase of intracellular calcium [19]. To
compare the cytosolic calcium response, we quantified the
peak of cytosolic calcium increase induced by 60 mM KCl
or 1 μM thapsigargin for 30 min (Figure 1B). Representa-
tive confocal images and trends of cytosolic calcium levels
produced by thapsigargin showed a rapid and acute in-
crease in calcium concentration which returned to basal
levels after 2 min (Additional file 2: Figure S2A and B).
Treatment with thapsigargin clearly resulted in an ap-
proximately a 3-fold increase in cytosolic calcium levels
compared with the effect of KCl, in both cell types
(Figure 1B). Additional studies with other calcium
mobilizing agents; 4-BrA23187 plus 6 mM Ca2+ and
Figure 1 Effect of cell depolarization on calcium regulation in striatal cells. A, B striatal cells were loaded with Fluo3 AM and cytosolic
calcium was measured using confocal microscopy. Fluo3 fluorescence changes were measured after cells were treated with 60 mM KCl for
30 min. Fluo3 intensity variations represent changes in cytosolic calcium levels and are expressed using the pseudo ratio ΔF/F0 (see Methods).
B, quantitative analysis of 4 independent experiments of striatal cells treated with 60 mM KCl and 1 μM thapsigargin. No differences in cytosolic
calcium peak were observed when wild type and mutant cells were compared. Data correspond to the mean ± S.E.M. of four independent
experiments. * p < 0.05 compared with untreated wild type cells, ** p < 0.05 compared with untreated mutant cells, # p < 0.05 compared to with
wild type cells treated with KCL, and ## p < 0.05 compared to mutant cells treated with KCL. C, D clonal striatal cells were loaded with Rhod2
AM/MitoGreen and treated with 60 mM KCl during 30 min for mitochondrial calcium determinations using confocal microscopy. KCl induced a
mitochondrial calcium increase in both cell types, with no significant differences between wild type and mutant cells. Mitochondrial calcium
levels were represented using pseudo ratio ΔF/F0. D, quantitative analysis of 4 independent experiments shows an increased mitochondrial
calcium levels in both mutant and wild type cells exposed to KCl. Interestingly, mutant cells treated with 1 μM thapsigargin for 30 min showed a
severe decrease in mitochondrial calcium uptake compared with wild type cells. Data correspond to the mean ± S.E.M. of four independent
experiments. * p < 0.05 compared with wild type cells treated with KCl, ** p < 0.05 compared with mutant cells treated with KCl, and # p < 0.05
compared to mutant cells treated with KCL.
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calcium between wild and mutant cells (Additional file 2:
Figure S2C). However, treatment with 4-BrA23187
(1nM) plus 6mM Ca2+ induced a significantly greater
increase in cytosolic calcium levels compared to KCl
treatment (Additional file 2: Figure S2C). In addition,
we evaluated mitochondrial calcium levels in wild typeand mutant huntingtin expressing cells exposed to KCl
and thapsigargin during 30 min (Figure 1C, D). KCl pro-
duced a consistent increase in mitochondrial calcium
levels, with a similar pattern in wild type and mutant cells
(Figure 1C). In contrast, calcium overload induced by
thapsigargin resulted in a significant decrease in mito-
chondrial calcium uptake in mutant cells, whereas wild
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calcium (Figure 1C, D). Quantitated data of striatal cells
treated with thapsigargin for 30 min consistently
showed that the abnormal increase in cytosolic calcium
deregulated mitochondrial calcium uptake in striatal
cells expressing mutant huntingtin (Figure 1D). In
addition, for all studies presented in this paper, vehicle
studies were made. Vehicle treatments were not in-
cluded because they did not show significant changes
compared to untreated cells.
Cyclosporine A prevented mitochondrial depolarization
induced by thapsigargin but not by H2O2 in mutant
huntingtin cells
There is evidence that pathological cytosolic calcium in-
crease can activate the mitochondrial permeability tran-
sition pore (mPTP) [30]. In general, the opening of mPTP
has been associated with the collapse of mitochondrial
membrane potential, complex I deficiency and changes in
free radical levels, and is thought to be a pathologic con-
dition involved in cell injury [31-33]. Therefore, we eva-
luated mitochondrial membrane potential changes in
striatal cells exposed to thapsigargin, with or without
treatment with 0.5 μM cyclosporine A (CsA), and inhibi-
tor of mPTP opening [30] for 2 h (Figure 2A, B, and C).
Figure 2A and B shows representative confocal images of
striatal cells loaded with MitoRed, a mitochondrial poten-
tial indicator, and exposed to 1 μM thapsigargin with or
without pretreatment with 0.5 μM CsA. Previously, we
have validated the use of this mitochondrial potential dye
by comparing it to tetramethylrhodamine methyl ester
(TMRE), a very well established mitochondrial potential
dye in clonal striatal cells [18,19]. These studies demon-
strated that treatment of both wild type and mutant cells
with the mitochondrial uncoupler trifluorocarbonylcya-
nide phenylhydrazone (FCCP) (10 μM) resulted in a simi-
lar robust decrease in MitoRed and TMRE fluorescence,
indicating a loss of mitochondrial potential [18]. Treat-
ment of mutant cells for 30 min with thapsigargin resulted
in mitochondrial membrane depolarization, an effect that
was not observed in wild type cells (Figure 2A). Pre-
treatment with CsA for two hours prevented mitochon-
drial impairment induced by thapsigargin in mutant cells
(Figure 2B). Quantitative analysis of striatal cells treated
with 60 mM KCl for 30 min, 1 μM thapsigargin for 30
min, 1 μM thapsigargin + pretreatment with 0.5 μM CsA
for 2 h, or pretreatment with 0.5 μM CsA for 2 h, showed
that CsA inhibited by nearly 80% the reduction of mito-
chondrial potential induced by thapsigargin in mutant
cells (Figure 2C). Noteworthy, CsA did not induce signifi-
cant changes in mitochondrial membrane potential of wild
type and mutant cells treated with 60 mM KCl for 30 min
(Figure 2C). However, thapsigargin treatment significantly
affected mitochondrial function in mutant huntingtinexpressing cells, indicating that high cytosolic calcium
levels mediated the mitochondrial impairment observed
in mutant cells. Interestingly, correlation analysis of cyto-
solic calcium and mitochondrial potential levels in striatal
cells under the indicated conditions showed that mito-
chondrial depolarization had a strong dependency on
the calcium concentration in mutant huntingtin cells
(Figure 2D). In addition, mitochondrial potential loss was
not present in mutant cells treated with KCl, but it was
observed in cells treated with 1 nM 4-BrA23187+ 6 mM
Ca2+, which significantly increased cytosolic calcium com-
pared to KCl (Additional file 2: Figure S2), showed a mild
but significant mitochondrial depolarization and decreased
mitochondrial calcium uptake compared with wild type
cells (Additional file 3: Figure S3). Further, we have pre-
viously reported that treatment with 1nM 4-BrA23187 did
not induce significant changes in mitochondrial potential,
mitochondrial calcium uptake, and cell viability [18].
Accumulative evidence suggests that mPTP could be
activated in response to calcium stress generating mito-
chondrial depolarization, mitochondrial calcium defects
and reduced ATP production [30,34]. Oxidative stress has
been involved in the pathogenesis of HD [17,24]. It is pos-
tulated that mutant huntingtin interferes with transcrip-
tional processes, leading to disruption of the expression
of genes involved in ROS response rather than direct
mitochondrial damage mediated by calcium disturbances
[17,24]. Therefore, we evaluated mitochondrial potential
levels in striatal cells exposed to an oxidant agent
(Figure 2E). Treatment with 100 μM H2O2 for 30 min re-
sulted in a robust reduction of mitochondrial potential in
both wild type and mutant cells (Figure 2D). Interestingly,
pretreatment with 0.5 μM CsA did not prevent mito-
chondrial potential loss induced by H2O2, indicating that
mPTP did not participate in mitochondrial impairment
induced by H2O2 in striatal cells. In conclusion, these re-
sults suggest a role for mPTP on mitochondrial damage
triggered by a pathological calcium increase in mutant
huntingtin cells.
Effect of FK-506 on thapsigargin-induced mitochondrial
impairment in mutant huntingtin cells
It has been reported that CsA could also inhibits the ac-
tivity of the phosphatase, calcineurin [35]. Therefore, to
determine the specificity of CsA for blocking the mPTP
and if the calcineurin pathway was involved in the mito-
chondrial dysfunction in mutant cells, we pre-treated
wild type and mutant cells with FK-506, which blocks
calcineurin, but lacks effect on mPTP [35,36]. Treat-
ment with 500 nM FK-506 for 2 h had no effect on
mitochondrial impairment induced by thapsigargin in
mutant striatal cells (Figure 3A, B), suggesting that CsA
specifically depended on its inhibition of mPTP in mu-
tant huntingtin cells.
Figure 2 (See legend on next page.)
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Figure 2 Treatment with Cyclosporine A prevents mitochondrial injury induced by thapsigargin in mutant HD cells. A, live confocal
images of MitoRed, an indicator of mitochondrial potential, in striatal cells, untreated and treated with 1 μM thapsigargin (Th) for 30 min.
Thapsigargin induces a significant decrease in the mitochondrial potential in mutant cells (see white arrows). Bar represents 10 μm. B, images
show that CsA protects mutant huntingtin cells exposed to thapsigargin from mitochondrial impairment. Bar represents 10 μm. C, quantification
of MitoRed intensities as relative units (ΔF/F0) in striatal cells treated for 30 min with experimental conditions as indicated. Data are the mean ±
S.E.M. of 4 independent experiments. *, p < 0.05 compared with wild type cells treated with thapsigargin; ** p < 0.05 compared with mutant cells
exposed to thapsigargin. D, correlation analysis of mitochondrial potential and cytosolic calcium observed in mutant cells treated with the
indicated conditions for 30 min. Cytosolic calcium was estimated from the peak levels. Mitochondrial potential were obtained after 30 min of
treatment for every condition. Data are expressed as the mean ± S.E.M. of 4 independent experiments. *, p < 0.05 compared to control; ** p < 0.05
compared to 60 mM KCL; ***, p < 0.05 compared to 4-BrA23187(1 nM) + 6 mM Ca2+. # compared to 60 mM KCL; ## compared to 4-BrA23187 + 6mM
Ca2+. E, confocal images of mitochondrial potential in striatal cells, untreated and treated with 100 μM H2O2 for 1h. Bar represents 10 μm. F, striatal cells
were incubated with 100 μM H2O2 for 1 h and mitochondrial potential was evaluated. MitoRed levels are show as relative units (ΔF/F0) at 1 h. Data is
expressed as the mean ± S.E.M. of 3 independent experiments.
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mitochondrial calcium uptake induced by thapsigargin in
mutant cells
Loss of mitochondrial potential could affect mitochondrial
calcium uptake and mitochondrial ROS production [19].
In our model, calcium increases induced by 4-BrA123 and
thapsigargin induced mitochondrial depolarization and
compromised mitochondrial calcium uptake in mutant
huntingtin cells (Figure 2 and Additional file 3: Figure S3)
[19]. To determine if the opening of mPTP is involved in
the inhibition of calcium uptake by the mitochondria in
mutant cells, striatal cells were pretreated with 0.5 μM
CsA for 2 h prior to exposure to thapsigargin and
mitochondrial calcium was determined with Rhod2 AM
(Figure 4A, B) [18]. Pre-incubation with CsA increased
mitochondrial calcium uptake in mutant cells exposed to
thapsigargin (Figure 4A, B). Previous studies have shown
that treatment with CsA or FK506 significantly reduced
the ionophore-induced rise in cytosolic calcium and mito-
chondrial depolarization in both neurons and astrocytes
[37]. Interestingly, in wild type cells, CsA reduced
mitochondrial calcium increase induced by thapsigargin
(compare both cell types in Figure 4B). These observations
suggest that mPTP could play an active role in normal
mitochondrial calcium uptake in striatal cells.
Ruthenium red failed to prevent mitochondrial
dysfunction induced by pathological calcium increases in
clonal striatal cells
Ruthenium red, an inhibitor of the mitochondrial calcium
uniporter, that prevents mitochondrial calcium uptake
[11], rescued mutant striatal cells from cell death and
mitochondrial depolarization induced by the treatment
with the mitochondrial toxin 3-nitropropionic acid (3-NP)
[11]. Therefore, we tested the effect of ruthenium red
on the thapsigargin-induced loss of calcium uptake
and depolarization by the mitochondria in mutant cells
(Figure 4C and D). Figure 4C shows representative plotsof mitochondrial calcium levels in striatal cells pre-treated
with ruthenium red and exposed to 1 μM thapsigargin. In
mutant striatal cells the treatment with ruthenium red
treatment did not prevent the reduction of mitochondrial
calcium uptake (Figure 4C, D). In contrast, ruthenium
red prevented the mitochondrial calcium uptake in-
duced by thapsigargin in wild type cells, suggesting the
maintenance of a normal mitochondrial calcium regu-
lation (Figure 4C, D). More importantly, pre-treatment
with ruthenium red did not prevent mitochondrial depo-
larization induced by calcium stress in mutant huntingtin
cells (data not shown). These data indicate that the mito-
chondrial calcium uniporter is not involved in the mito-
chondrial dysfunction observed in mutant huntingtin cells
exposed to calcium stress.
Cyclosporine A prevented Reactive Oxygen Species (ROS)
production and mMTP opening induced by thapsigargin
in mutant huntingtin cells
ROS production is often used as a measure of mito-
chondrial function [38-41]. Given that treatment with
thapsigargin resulted in mitochondrial dysfunction in
mutant cells, and that CsA prevented this impairment,
we determined if thapsigargin affected ROS production
in wild type and mutant cells. Cells were loaded with
2′,7′-dichlorodihydrofluorescein diacetate (2.7-DCF), a
cell-permeant indicator of ROS, and treated with thapsi-
gargin and CsA alone or in combination. Because there
were a few reports that indicated some problems with the
use of 2.7-DCF for ROS determinations [42], we per-
formed control studies in where striatal cells loaded with
2.7-DCF were treated with 500 μM H2O2 for 30 min and
changes in 2.7-DCF fluorescence intensity were evaluated
by confocal microscopy (Additional file 4: Figure S4).
Treatment with H2O2 produced an increase in ROS
production that was consistently detected by 2.7-DCF
(Additional file 4: Figure S4). Thapsigargin induced a 3 to
5-fold increase of ROS production in wild type and
Figure 3 Effects of FK-506 on mitochondria impairment induced
by thapsigargin in mutant huntingtin cells. A, wild type and mutant
cells were incubated with 500 nM FK-506, an inhibitor of calcineurin
activity, for 2 h prior to mitochondrial potential determinations using
MitoRed. Striatal cells loaded with MitoRed were exposed to 1 μM
thapsigargin (Th) for 30 min, and mitochondrial potential was
evaluated using confocal microscopy. Treatment with thapsigargin
reduced mitochondrial potential levels in mutant striatal cells pre-treated
with FK-506, indicating that calcineurin activity was not playing a role in
mitochondrial impairment induced by calcium stress in mutant
huntingtin cells. B, quantitation of MitoRed intensities, which
represents mitochondrial potential levels, as relative units at 30 min
(ΔF/F0) in striatal cells treated with conditions indicated. Data are
expressed as the mean ± S.E.M. of 4 independent experiments.
*, p < 0.05 compared with wild type cells treated with thapsigargin;
** p < 0.05 compared with wild type cells treated with thapsigargin.
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reaching higher ROS levels in mutant than in wild type
cells (Figure 5B and Additional file 1: Figure S4B) as
detected with 2.7-DCF. To corroborate these findings, we
evaluated superoxide levels induced by thapsigargin using
the MitoSOX™ (MitoSOX) in the same experimental para-
digm (Additional file 4: Figure S4C). Mutant cells con-
sistently produced more superoxide than wild type cells in
response to thapsigargin treatment (Additional file 4:Figure S4C). Interestingly, CsA treatment significantly
prevented the ROS production induced by calcium stress
in both cell types (Figure 5B). Quantitated data of 2.7-
DCF fluorescence intensity from 4 independent experi-
ments shows a significant increase in ROS production in
the mutant cells compared with wild type cells (Figure 5B).
This increase in ROS production was prevented by CsA
treatment (Figure 5B) suggesting that inhibition of mPTP
by CsA reduced ROS levels in mutant huntingtin express-
ing cells exposed to pathological calcium overload.
The mPTP is defined by its inhibition by CsA, which
binds to mitochondrial cyclophilin D and blocks the
calcium-induced mPTP opening [35,36,43]. Opening of
mPTP causes the mitochondrial inner membrane (MIM)
to become permeable and leads to the loss of the ions con-
centration gradients and dissipation of the mitochondrial
potential [31,32]. To determine if the mPTP was open
in mutant cells exposed to calcium overload, we used
the cobalt/calcein AM quenching method (Figure 5C-E)
[35,44]. In mutant cells treated with thapsigargin, cobalt
quenched calcein fluorescence inside the mitochondria
due to free movement of these molecules through an open
mPTP, decreasing by 35% calcein fluorescence intensity
(Representative images in Figure 5C and quantitative data
in Figure 5E). However, when mutant cells were treated
with thapsigargin plus CsA, mitochondrial calcein fluo-
rescence was retained, suggesting that CsA closed the
mPTP, preventing cobalt entry (Representative images in
Figure 5D and quantitative data in Figure 5E). As a con-
trol, we evaluated cobalt quenched calcein intensity in
striatal cells treated with thapsigargin in the presence of
10 μM of the mitochondrial uncoupler FCCP (Figure 5E).
FCCP treatment significantly prevented loss of calcein
fluorescence from striatal cells mitochondria, indicating
that mPTP has a strong dependency on pathological cal-
cium increases (Figure 5E) [44].
To complement these results, we tested if the blocking
of mPTP by CsA could have an effect on cell viability in
striatal cells exposed to calcium stress (Additional file 5:
Figure S5). Striatal cells were treated with 1 μM thapsigar-
gin (Th), or 1 μM thapsigargin + 0.5 μM CsA (Th + CsA)
for 24 h and cell viability was estimated with calcein AM
(green) and Propidium Iodide (PI) staining. Calcein stai-
ning represents cells that are metabolically active and PI
staining indicates a loss of the nuclear membrane integrity
[11]. Treatment with thapsigargin significantly decreased
cell viability (calsein/PI fluorescence ratio) in mutant hun-
tingtin cells (Additional file 6: Figure S6). Inhibition of
mPTP opening with CsA prevented cell viability loss
induced by thapsigargin in mutant cells. These findings
indicated that pathological calcium stress could affect
mitochondria function, and then compromise cell viability
in mutant huntingtin cells, through the opening of mito-
chondrial permeability transition pore.
Figure 4 Treatment with Cyclosporine A improved mitochondrial calcium uptake in mutant huntingtin cells exposed to calcium
overload. A, striatal cells were loaded with Rhod2 AM dye to determine mitochondrial calcium levels in cells exposed to 1 μM thapsigargin (Th)
during 30 min. Thapsigargin treatment severely decreased mitochondrial calcium uptake. Striatal cells were incubated for 2 h with 0.5 μM
Cyclosporine A (CsA) prior to determination of mitochondrial calcium levels in response to thapsigargin treatment. CsA prevented the
mitochondrial calcium decrease induced by thapsigargin in the mutant cells. B, quantification of mitochondrial calcium levels from 4
independent experiments obtained from cells exposed to thapsigargin for 30 min. *, p < 0.05 compared with mutant cells treated with
thapsigargin alone. C, wild type and mutant cells were pre-treated with 1 μM ruthenium red for 1 h, before addition of 1 μM thapsigargin. Ruthenium
red did not prevent the mitochondrial calcium decrease induced by thapsigargin in mutant cells. D, quantification of mitochondrial calcium uptake at
30 min shows that thapsigargin only induced a significant increase in mitochondrial calcium only in wild type cells. Thapsigargin treatment of mutant
cells resulted in a pronounced decrease in mitochondrial calcium uptake by mutant cells, and this event was partially blocked by CsA pre-treatment.
Data are the mean ± S.E.M. of 3 separate experiments. *, p < 0.05 compared with mutant cells treated with thapsigargin; **, p < 0.05 compared with
mutant cells treated with thapsigargin plus CsA. p < 0.05 for nonpaired Student’s t test.
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induced by thapsigargin in mutant huntingtin cells
Mitochondria are morphologically dynamic organelles dis-
tributed throughout the cell by fission and fusion to form
individual units or interconnected networks [25,26,45]. In
normal healthy cells, there is equilibrium between mito-
chondria fusion and fission [46,47]. Evidence from expe-
rimental models suggests that mitochondrial fission and
fusion appears to be altered in HD, contributing to
neuronal dysfunction and death [21,22,45,48]. Mutant
huntingtin appears to physically impair mitochondrialmobility and trafficking [21]. Increasing length of polyglu-
tamine repeats length in mutant huntingtin constructs
expressed in HeLa cells results in greater mitochondrial
fragmentation and reduced ATP levels [22]. More impor-
tantly, we showed that in basal conditions mutant cells
displayed more fragmented mitochondria than wild type
striatal cells, and that this effect was prevented by the
increase of Nrf2 expression, a transcriptional factor key in
the regulation of ROS defense mechanism [24]. Mitochon-
drial fragmentation was accompanied with alterations on
the expression levels of Drp1 and Opa1, key regulators of
Figure 5 Cyclosporine A prevented Reactive Oxygen Species (ROS) production and mMTP opening induced by thapsigargin in mutant
huntingtin cells. A, representative fluorescence images of 2,7-dichlorofluorescein indicating the levels of ROS striatal cells challenged with 1 μM
thapsigargin (Th) for 1 h, CsA for 2 h and both. Increased levels of ROS in striatal cells treated with thapsigargin (A and B) were prevented by
pretreatment with CsA. Bar =10 μm. B, Quantitative ROS levels. Data are the mean ± S.E.M. of 3 independent experiments. *, p < 0.05 compared
with thapsigargin treated wild type cells; **, p < 0.05 compared with thapsigargin treated wild type cells. ***, p < 0.05 compared with mutant cells
treated with thapsigargin. p < 0.05 by non-paired Student’s t test. C and D, representative fluorescence images of wild type (C) and mutant cells
(D) cells loaded with calcein AM/Cobalt for 30 min indicating the state of the mPTP [35]. Cells were treated with 1 μM thapsigargin (Th) for 30
1 h and pre-treated with 0.5 μM CsA for 2 h. Treatment with thapsigargin decreased calcein fluorescence intensity in mutant cells indicating that
calcium overload opens the mPTP (C). Treatment with CsA prevented the loss of calcein intensity in mutant cells, closing the mPTP. In C and D
bar represents 10 μM. E, Calcein intensity levels in striatal cells treated with indicated conditions for 1 h. Quantitation in treated mutant cells
revealed that thapsigargin induced mPTP opening. CsA prevented mPTP opening in mutant cells exposed to thapsigargin. Mitochondria depolarization
induced by FCCP did not affect mPTP in mutant huntingtin cells. Data correspond to the mean ± S.E.M. of 4 independent experiments. * p < 0.05
compared with wild type cells treated with thapsigargin. ** p < 0.05 compared with mutant cells treated with thapsigargin.
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these previous findings, we evaluated if calcium overload
affects mitochondrial morphology of clonal striatal cells
expressing mutant huntingtin. To evaluate changes in
mitochondrial morphology, wild type and mutant striatal
cells were transfected with a Mito-GFP construct and
were mounted in a microscope chamber for time-lapse
studies 24 h later. Mitochondrial morphology changes
were evaluated for striatal cells treated with thapsigargin
and thapsigargin plus CsA (Figure 6). Figure 6 shows rep-
resentative images of mitochondrial morphology of wild
type and mutant cells expressing Mito-GFP treated with
thapsigargin for 1 h. As previously shown, mitochondria
from mutant cells were more fragmented than those from
wild type cells (Figure 6A, B) [24] and pathological in-
crease in calcium induced by thapsigargin enhanced mito-
chondrial fragmentation in mutant cells compared with
wild type cells (Figure 6A, B). Next, we assessed the effect
of the pharmacological blockage of mPTP with CsA on
mitochondrial morphology in striatal cells treated with
thapsigargin (Figure 6C, D, E). Striatal cells were pre-
treated with CsA for 2 h prior to thapsigargin treatment
and their evaluation by time-lapse (Figure 6C, D, E). CsA
reduced mitochondrial fragmentation induced by calcium
overload in mutant huntingtin cells (Figure 6C, D, E), fur-
ther suggesting that mPTP could play a role in mito-
chondrial impairment induced by calcium in mutant
huntingtin cells.Mutant huntingtin expression induced mitochondrial
impairment in cortical neurons exposed to pathological
increases in calcium
Here, we have observed that in clonal striatal cells, a cell
model expresses physiological levels of mutant huntingtin,
that calcium overload induced mitochondrial impairment
and oxidative stress. Therefore, we expressed different poly-
glutamine versions of exon 1 of the huntingtin protein in
primary cortical neurons. Q25-GFP was considered repre-
sentative of normal huntingtin protein, whereas Q104-GFP
was used to mimic the effects of mutant huntingtin.
Figure 7A shows representative images from cortical neu-
rons transfected with GFP (control vector), Q25-GFP and
Q104-GFP labeled with calcein blue as a neuronal morph-
ology indicator. Transfected neurons were loaded with
MitoRed to observe mitochondrial potential changes in
response to calcium stress (Figure 7B). As previously
observed in mutant striatal cells, calcium stress induced a
significant mitochondrial membrane potential loss in cor-
tical neurons expressing Q104-GFP (Figure 7B, C, and rep-
resentative images in Additional file 6: Figure S6).
Representative graphs and quantitated studies showed that
thapsigargin rapidly reduced mitochondrial membrane
potential (Figure 7B, C).Blockage of mitochondrial permeability transition pore
(mPTP) prevented mitochondrial dysfunction induced by
thapsigargin in cortical neurons expressing mutant
huntingtin
The effect of CsA on mitochondrial membrane potential
changes induced by calcium overload was evaluated in
cortical neurons expressing GFP, Q25-GFP, or Q104-
GFP (Figure 7D, E). Cortical neurons transfected with
GFP or Q25-GFP did not show significant changes in
mitochondrial membrane potential in response to thap-
sigargin treatment with or without CsA pre-treatment
(Figure 7D, E). More importantly, CsA abolished mito-
chondrial membrane potential loss induced in cortical
neurons that expressed Q104-GFP, further strengthening
our proposal that mPTP plays an important role in
mitochondrial dysfunction induced by calcium stress in
mutant huntingtin expressing cells (Figure 7D, E).
Altogether, these results indicate that expression of
mutant huntingtin could have a negative effect on mito-
chondria function, reducing their capacity to respond to
calcium stress. This effect is likely mediated by mPTP
opening in mutant huntingtin expressing cells, result-
ing in an increased oxidative stress, calcium handling de-
fects, mitochondrial fragmentation and finally in
neuronal dysfunction.
Discussion
Our principal finding is that mutant huntingtin affects
mitochondrial function by modifying mitochondrial cal-
cium homeostasis, mitochondrial morphology and ROS
handling through opening of mPTP. These mitochondrial
impairments in mutant huntingtin-expressing cells only
occurred after calcium overload, simulating pathophysio-
logical conditions that may occur in HD (Figure 8). CsA, a
well-accepted inhibitor of mPTP opening, prevented these
events, further supporting the participation of mPTP in
the mitochondrial dysfunction (Figure 8). In addition, CsA
prevented cell viability loss induced by calcium stress in
mutant huntingtin cells (Additional file 5: Figure S5), con-
firming the importance that mitochondrial impairment
have in the striatal neuronal dysfunction. Interestingly, we
showed that huntingtin protein colocalized with MitoRed
(mitochondrial marker) and cytochrome c in untreated
striatal cells (Additional file 1: Figure S1). Also, previous
studies of mitochondria subfractionation indicated that
huntingtin was associated with the outer mitochondrial
membrane in striatal cells [20]. Therefore, it is possible
that binding of mutant huntingtin with mitochondria sen-
sitizes this organelle to calcium stress leading to mPTP
opening. Interestingly, mitochondrial injury induced by
mutant huntingtin in response to calcium stress was repli-
cated in cortical neurons transfected with mutant con-
structs containing an expanded polyglutamine domain
(Figure 7), confirming that observations presented in this
Figure 6 (See legend on next page.)
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Figure 6 Mitochondrial fragmentation induced by calcium overload was prevented by inhibition of mPTP in mutant huntingtin cells.
A, striatal cells transfected with Mito-GFP protein were treated with 1 μM thapsigargin (Th) during 60 min before live fluorescence images were taken.
Images were acquired from full resolution images obtained with 63X objective in a Zeiss Axiovert LED fluorescence microscope. Thapsigargin
treatment induced a significant fragmentation of mitochondria in mutant compared with wild type cells. Bar = 10 μm. B, magnification of boxed
regions from A to emphasize differences of mitochondrial morphology in striatal cells. Bar = 5 μm. C, striatal cells transfected with Mito-GFP protein
were treated with thapsigargin (Th) plus cyclosporine A (CsA) during 60 min and live fluorescence images were obtained. Images were acquired from
full resolution images obtained with 63X objective in a Zeiss Axiovert LED fluorescence microscope. Thapsigargin treatment induced significant
fragmentation of mitochondria in mutant compared with wild type cells. Mitochondria fragmentation produced by calcium stress was abolished by
mPTP closure induced by 0.5 μM CsA treatment for 2 h. Bar = 10 μm. D, magnification of boxed regions from A to emphasize differences of mitochon-
drial morphology in striatal cells. Bar = 5 μm. E, quantitation of mitochondrial length of 4 independent experiments showed significant mitochondria
fragmentation in mutant cells exposed to thapsigargin and this effect was prevented by co-treatment with CsA. Data correspond to the mean ± S.E.M.
of 4 independent experiments. * p < 0.05 compared with wild type treated with thapsigargin. ** p < 0.05 compared with mutant cells treated
with thapsigargin.
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tin induced mitochondrial calcium handling defects in iso-
lated mitochondrial from striatal cells [17-19]. From these
and other findings we conclude that mitochondrial dys-
function in mutant cells could be triggered by cumulative
cytosolic calcium increases and that these effects could
contribute to the progression of striatal neuronal death
reported in HD [49] (Figure 8).
It has been shown that elevated calcium can poten-
tiate cell death-related events, including mPTP opening
[30,50]. Interestingly, CsA prevented the reduction in
mitochondrial calcium uptake, mitochondrial potential
loss, and cell viability loss in mutant cells exposed to
thapsigargin; in contrast to ruthenium red, which did
not show any protective effect, indicating that regular
mitochondrial calcium uptake mediated by uniporter is
not involved in mitochondrial impairment induced by
mutant huntingtin. In addition, FK-506, an inhibitor of
calcineurin activity, had no significant effect on mito-
chondrial dysfunction induced in mutant striatal cells
by calcium overload, indicating that CsA is specifically
acting on mPTP opening [35].
In addition, we observed that treatment with H2O2 and
FCCP induced a similar mitochondrial impairment in
both wild type and mutant huntingtin cells, and this effect
was not prevented or ameliorated by CsA treatment
(Figure 2D). Our observations support an interesting work
recently published by Wang et al., showing that YAC128
mouse embryonic fibroblasts that express mutant hun-
tingtin exhibit a high level of mitochondrial Ca2+ load and
elevated superoxide levels compared with wild type
cells [34]. Increased mitochondrial oxidative stress was
dependent on mitochondrial Ca2+ overload in HD cells,
because blocking mitochondrial Ca2+ uptake prevented
elevated superoxide production [34]. In general, these
observations are complementary with the evidence pre-
sented here and indicate that mitochondrial dysfunction
triggered by mutant huntingtin is dependent on patho-
logical calcium deregulation, an event that could be res-
ponsible for mPTP opening in mutant cells [51,52].Previous evidence suggests that a toxic gain of function
of cyclophilin D (CyP-D) could be responsible of mito-
chondrial impairment induced by calcium [30-32]. For
example, studies in striatal mitochondria preparations
show an increased sensitivity to calcium stress compared
with cortical mitochondria, which was partially prevented
by CsA [52]. In addition, Shirendeb et al. evaluating the
mRNA levels of mitochondrial structural genes showed
that CyP-D was upregulated in HD patients, and this up-
regulation increased as HD progressed [26]. These obser-
vations suggest that mPTP could be playing an active role
in mitochondrial function in striatal cells and further
supports its involvement in mitochondrial dysfunction
mechanisms previously reported in HD.
Interestingly, we observed that mutant striatal cells
transfected with Mito-GFP and exposed to thapsigargin
showed an increased mitochondrial fragmentation com-
pared with wild type cells (Figure 6). More importantly,
pre-treatment with CsA prevented mitochondrial frag-
mentation in mutant striatal cells treated with thapsi-
gargin, in agreement with previous reports showing that
expression of increasing polyglutamine repeats results in
greater mitochondrial fragmentation and reduced ATP
levels in HeLa cells [22]. Our observations complement
previous observations where striatal calbindin-positive
neurons in HD patients showed a significant and pro-
gressive reduction in the number of mitochondria [23].
Also, we recently examined, changes in mitochondrial
dynamics and structure in wild type and mutant cells in
response to oxidative stress [24]. Mutant huntingtin cells
display more fragmented mitochondria than wild type
cells, concurrent with alterations in the expression levels
of dynamin-related protein 1 (Drp1) and Opa1, key re-
gulators of mitochondrial fission and fusion, respectively
[24]. Lastly, mitochondrial PCR array studies using HD
caudate nucleus specimens showed an increased mRNA
expression of Drp1, fission 1 (Fis1), and decreased expres-
sion of: mitofusin1 (Mfn1), mitofusin 2 (Mfn2), and Opa1
relative to the control individuals [23]. These are proteins
involved in mitochondrial localization, membrane
Figure 7 Mitochondrial impairment induced by thapsigargin was prevented by cyclosporine A in neurons that expressed mutant
huntingtin. A, representative fluorescence images of cortical neurons loaded with calcein blue AM (Calcein B) and transfected with GFP alone,
Q25-GFP (normal huntingtin), or Q104-GFP (mutant huntingtin). Normal and mutant huntingtin expression is indicated by GFP fluorescence
intensity (white arrows) and calcein blue staining reveals neuronal morphology. Bar = 10 μm. B, transfected neurons were loaded with MitoRed
for determination of mitochondrial potential. Representative trends show that the expression of Q104-GFP significantly reduced mitochondrial
potential during treatment with 1 μM thapsigargin (Th). C, quantitation of mitochondrial potential levels showed significant mitochondrial
damage in neurons that expressed Q104-GFP. Data correspond to the mean ± S.E.M. of 4 independent experiments. *, p < 0.05 compared with
Q25-GFP neurons treated with thapsigargin. D, neurons transfected with GFP, Q25-GFP, or Q104-GFP were treated with 0.5 μM CsA for 2 h
before mitochondria potential measurements. Representative trends show that the inhibition of mPTP by CsA prevented mitochondria injury
induced by thapsigargin in Q104-GFP positive neurons. E, quantitation of mitochondria potential levels shows that CsA treatment significantly
prevented mitochondrial impairment in neurons expressing Q104-GFP compared with the other conditions. Data correspond to the mean ± S.E.M. of 4
independent experiments. * p < 0.05 compared with Q25-GFP neurons treated with thapsigargin. ** p < 0.05 compared with Q104-GFP neurons treated
with thapsigargin.
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Figure 8 Role of mPTP in mitochondrial damage induced by mutant huntingtin. Representative scheme showing the interplay between
calcium regulation, mitochondrial function and mPTP in mutant huntingtin cells. (A), in response to controlled cytosolic calcium increase striatal
cells can efficiently regulate calcium homeostasis and mitochondrial function even with the presence of mutant huntingtin. However,
pathological calcium increases activated mPTP inducing mitochondrial depolarization and oxidative stress conducing to neuronal dysfunction
(B). These two signs of mitochondrial damage can be prevented by inhibition with CsA, an inhibitor of mPTP, which improve mitochondrial
function and neuronal health.
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leled mitochondrial impairment [23,26]. Therefore, our
findings in conjunction with previous evidence reveal that
both mitochondrial function and altered mitochondrial
morphogenesis could play an important role in the patho-
genesis of HD.
Mice lacking of CyP-D a key regulator of mPTP, are
resistant to oxidative stress and mitochondrial toxicity
mediated by calcium [53], indicating that striatal mito-
chondria could be selectively more vulnerable to the mPTP
opening. Despite our results suggesting that mitochondrial
dysfunction could be mediated by mPTP opening in HD,
it was recently shown that increased neuronal mito-
chondria calcium retention by CyP-D failed to ameliorate
both behavioral and neuropathological features of R6/2
mice [51]. R6/2 mice are the most widely used HD study
models because of its relatively rapid-onset and robust
phenotype [54,55]. Even though the phenotype and neuro-
pathology observed in R6/2 lines replicate several features
observed in HD patients, R6/2 mice may not model cri-
tical aspects of the pathogenic process in HD [51]. An-
other important consideration is that negative outcome ofCyP-D ablation could be due to compensatory mecha-
nisms during development, which could affect mito-
chondrial function [51]. In addition, parameters like ROS
production, mitochondrial membrane potential and mito-
chondrial fragmentation were not evaluated by Perry
et al., [51], compared with our studies in where we eva-
luated all parameters mentioned above. More importantly,
previous studies of our group showed a decreased expres-
sion of CyP-D protein levels in mutant huntingtin cells
compared to wild type [56]. Therefore, it is plausible that
greater association between mutant huntingtin and mito-
chondria (Additional file 1: Figure S1) facilitates mPTP
opening by calcium stress and this could ultimate affects
mitochondria function. However, additional experiments
are needed to determine if the interaction of mutant hun-
tingtin with other mitochondrial proteins could modify
protein structures relevant for mPTP opening and thus
contribute to the pathogenesis of HD.
Conclusions
Taken together, our observations indicate that mutant
huntingtin affects mitochondrial and neuronal function
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trigger by accumulative calcium overload in striatal cells
and cortical neurons. mPTP may affect mitochondrial
calcium homeostasis, ROS production, and mitochon-
drial fusion/fission which contributes to the dysfunction
of mitochondria in striatal cells, and thus likely is an im-
portant factor in the neurodegenerative processes that
occur in HD brain.
Methods
Materials and plasmids
Chemicals, culture media and serum were obtained from
Sigma-Aldrich (St. Louis, MO, USA), Roche (Alameda,
CA, USA), and Invitrogen (Carlsbad, CA, USA). Fluo-3
AM, Rhod-2 AM, thapsigargin, Mitotracker Green
FM (MTG), Mitotracker Red® CM-H2XRos (MitoRed),
MitoSOX™ (MitoSOX), cyclosporine A (CsA), FK 506,
KCl, calcein AM (green), calcein AM (blue), Propidium
Iodide (PI), cobalt chloride, FCCP, DAPI, and 5-(and-6)-
chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate,
acetyl ester (2,7-DCF) were obtained from Molecular
Probes (Eugene, OR, USA). Anti-huntingtin antibody
(mAB2166) was obtained from Chemicon International
(Temecula, CA, USA) and anti-cytochrome C was obtained
from BD Biosciences (San Jose, CA, USA). Q25-GFP and
Q104-GFP constructs were kindly provided by Dr. Mathieu
Lesort (UAB, AL, USA). Q25-GFP and Q104-GFP contain
the N-terminal and poly Q region of huntingtin fused with
GFP. Mito-GFP was kindly provided by Dr. Yisang Yoon
(Medical College of Georgia, GA, USA).
Cell culture
Striatal cells culture
Conditionally immortalized striatal progenitor cell lines
STHdhQ7/Q7 expressing endogenous wild type huntingtin
and STHdhQ111/Q111 cells expressing comparable levels of
mutant huntingtin with 111 glutamines [27] were used.
These cell lines, a generous gift from Dr. M. E. MacDonald,
were prepared from wild type and homozygous
HdhQ111/Q111 knock-in mice as previously described
[27]. Culture conditions were the same as described in
previous studies [18,19,56].
Primary neuron culture and transfection
Primary cortical neuronal cultures from rat embryonic
forebrains were prepared as previously described with
some modifications [57]. Briefly, the brain of rats at
embryonic day 17– 18 was obtained. Cortices were dis-
sected, treated with 0.05% trypsin at 37°C for 30 min,
and gently triturated with a fire polished glass Pasteur
pipette. Cells were plated onto poly-D-lysine-coated
coverslips or glass-bottom dishes in Minimum Essential
Media (MEM) with 5% fetal bovine serum, 100 U/mL
penicillin, and 100 μg/mL streptomycin. After threehours of seeding, medium was replaced with Neurobasal
medium (NBM) supplemented with 0.4 mM glutamine
and B27. To prevent proliferation of glial cells and astro-
cytes, neuronal cultures were treated with 2 μM AraC
for 24 h. Half of the medium was replaced with fresh
neurobasal medium supplemented with 0.4 mM glutam-
ine and B27 every 3 days. All materials for cell culture
were from Invitrogen, CA, USA.
Neurons were transiently transfected with 0.8 μg of
plasmids using Lipofectamine 2000 (Invitrogen) at 7 days
in vitro (DIV) following manufacturer protocols. Imaging
experiments were performed at 9 DIV in a confocal
microscope.
Cell viability
Cell viability was determined by using the calcein-AM
(green) and Propidium Iodide (PI) (red) assay with some
modifications [11]. Briefly, non-fluorescent calcein-AM is
converted into green fluorescent calcein by intracellular
esterases and indicates the presence of active cell meta-
bolism. PI binds to nucleic acid generating a fluorescence
signal that indicates disruption of nuclear membrane.
After treatment, striatal cells were incubated with calcein-
AM (1 μM) and PI (5 μM) for 30 min at 37°C and then
live fluorescence images were taken in a fluorescence
microscope (Axiovert Colibri, Zeiss). Quantification of
fluorescence intensity was made using Image Pro 6 soft-
ware and cell viability was expressed as a calcein/PI ratio
of the signal obtained from the cells untreated and ex-
posed to indicate conditions.
Intracellular Reactive Oxygen Species (ROS) measurement
Clonal striatal cells were plated on poly-L-lysine-coated
coverslips (30,000 cells/coverslip) and treated with 1 μM
thapsigargin, in absence or presence of 0.5 μM CsA for 2 h.
After treatment, cells were incubated with the fluorescent
probe 2, 7-DCF (10 μM) in Krebs-Ringer-Hepes (KRH)
buffer supplemented with 5 mM glucose for 30 min
[19,58]. Coverslips were washed two times with PBS solu-
tion and fixed with 4% p-formaldehyde for 5 min. Cells
were photographed using a Zeiss Axiovision fluorescence
microscope integrated with a CCD digital cool camera
(Zeiss, Germany). Photographs were taken adjusting the
same exposure time and gain detector in order to diminish
the photobleaching of 2,7-DCF. Images quantification for
each separate experiment was carried out analyzing 30 im-
ages (10-15 cells per image) for every indicated condition
using Image-Pro Plus 6 software. Additionally, superoxide
levels were evaluated using MitSOX™ dye in striatal cells
treated with 1 μM thapsigargin during 1 h [57]. Cells grown
on 35-mm dishes were incubated with 20 μM Mitotracker
Green™ (MTG) and 200 nM MitoSOX Red for 20 min in
KRH buffer supplemented with 5 mM glucose [19]. MTG
accumulates in the lipophilic environment of live
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pendent of the mitochondrial potential [19]. Images were
acquired using a 488-nm argon laser to excite MTG and a
563-nm He-Ne laser to excite MitoSOX Red fluorescence.
Estimation of mitochondrial superoxide production was
quantified using Image-Pro Plus 6 software. Results in in-
tensity units were expressed as the average of fluorescence
signal (F) minus background fluorescence (F0) in every
image. Results in intensity units were expressed as average
of fluorescence signal (F) minus background fluorescence
(F0) in every image [19,58].Determination of mitochondria potential in live cells
Mitochondria membrane potential was determined using
the mitochondrial dye, Mitotracker® Red CM-H2XRos
(MitoRed) [18,19,57]. The validity of MitoRed as a reliable
mitochondrial membrane potential indicator was pre-
viously defined in Milakovic et al., 2006 and Quintanilla
et al., 2008 [18,19]. Striatal cells were loaded separately
with MitoRed and TMRM and then were treated with the
mitochondrial uncoupler FCCP (10 μM). Changes in in-
tensity were recorded using a confocal microscope [18].
Both indicators presented equal changes in mitochondrial
potential levels after FCCP treatment [18]. In addition,
mitochondrial potential was evaluated in striatal cells
treated with 1 nM 4-BrA23187 + 6 mM Ca2+ in the pre-
sence of 10 μM FCPP and mitochondrial potential was
evaluated (Additional file 3: Figure S3). The treatment
with 1 nM 4-BrA23187 did not induce a significant
change in mitochondrial potential, mitochondrial cal-
cium uptake, and cell viability [18]. Mutant and wild
type presented equal mitochondrial potential loss after
treatment (Additional file 3: Figure S3). Striatal cells
were grown on poly-L-lysine-coated coverslips and cul-
tured for 4 days. The cell cultures were then loaded for
30 min with MitoRed in KRH buffer supplemented with
5 mM glucose and 0.02% pluronic acid. Cells were then
mounted in a chamber on a confocal laser scanning
microscope (Leica SP2, Germany). Fluorescence changes
determined by MitoRed fluorescence were used as a
measure of mitochondria potential [18,19,57]. Signal from
control cells and cells treated with different stimuli were
compared using identical settings for laser power, and
detector sensitivity for each separate experiment. The im-
ages were analyzed with a LCS Leica confocal software
(Germany) and recorded as the mean MitoRed fluores-
cence signal per live cell. For each experiment, we ana-
lyzed MitoRed intensity changes in 10-15 cells in average.
Estimation of fluorescence intensity of MitoRed was pre-
sented as the pseudo-ratio (ΔF/Fo), which was calculated
using the following formula: ΔF/Fo = (F-Fbase)/(Fbase-B),
where F is the measured fluorescence intensity of the indi-
cator, Fbase is the fluorescence intensity before thestimulation, and B is the background signal determined
from the average of areas adjacent to the cells [18,19,57].
In situ evaluation of mitochondrial permeability transition
pore (mPTP)
mPTP opening was evaluated in striatal cells previously
loaded with 1 μM calcein AM (green) in presence of 1 μM
cobalt chloride for 30 min before treatment with thapsi-
gargin [35]. Quenching of free calcein by cobalt chloride
allows observing mitochondrial integrity as an mPTP indi-
cator [35,44]. Striatal cells loaded with calcein/cobalt
chrolide were treated with thapsigargin for 1 h and images
were taken using a confocal microscope. Loss of mito-
chondrial integrity or mPTP was evaluated from calcein
fluorescence intensity levels obtained from time-lapse im-
ages [35]. For each independent experiment, we analyzed
calcein AM intensity changes in 10-15 cells in average.
Cytosolic and mitochondrial calcium measurements
Cells grown on poly-L-lysine-coated 25 mm coverslips
(37°C) were loaded with 5 μM Fluo-3 AM, and 10 μM
Rhod-2 AM in KRH-glucose containing 0.02% pluronic
acid for 30 min. The fluorescence changes determined
by Fluo-3 represent the cytoplasmic calcium changes
[19], and Rhod-2 fluorescence indicates calcium changes
in the mitochondria [19,59,60]. To estimate Rhod-2
fluorescence pattern in live mitochondria, we used MTG
[19]. Fluorescence was imaged with a confocal laser-
scanning microscope (Leica TCS SP2) using a 40× water
immersion lens, as previously described [18]. Images
were acquired using a 488-nm Argon laser to excite
Fluo-3 fluorescence and a 563-nm He-Ne laser to excite
Rhod-2 fluorescence. Signals were collected at 505–530
nm (Fluo-3) and at 590 nm (Rhod-2). Fluorescence
background signal was subtracted from cell fluorescence
measurements in every experiment. The fluorescence
intensity variation was recorded from 10-20 cells on
average per experiment. Estimation of fluorescence
intensity of Fluo-3 and Rhod-2 were presented as a
pseudo-ratio (ΔF/Fo), as previously described [19].
Analysis of mitochondrial morphology
Mitochondrial morphology was analyzed as described pre-
viously with modifications [57]. Briefly, clonal striatal cells
were transfected with Mito-GFP using Lipofectamine
2000 for 24 h and subsequently replaced with fresh media.
We estimated a transfection efficacy of 35%. Striatal cells
expressing Mito-GFP were treated with CsA for 2 h pre-
vious to thapsigargin treatment and time-lapse images
were registered using fluorescence Zeiss microscope.
Mitochondrial length was analyzed as previously shown
[19,57]. Briefly, mitochondrial length was calculated using
the measured perimeter of identified objects, in striatal
cells positive for Mito-GFP staining using Image Pro 6
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chondrial population from 10-15 cells presented in each
image that was taken. For quantification purposes, we
measured around 15-18 images for experiment in each
condition indicated [19,57].
Statistical analysis
Results were expressed as the mean ± S.E.M., and were
analyzed using Student’s t test, or paired t test as indi-
cated. Differences were considered significant if p < 0.05
or p < 0.01, as indicated.Additional files
Additional file 1: Figure S1. Expression of huntingtin in clonal striatal
cells. Striatal cells were grown at glass coverslips and then were fixed and
stained with: anti-huntingtin antibody, anti-cytochrome antibody, DAPI,
and the mitochondrial indicator MitoRed to study the levels and the
localization of huntingtin. Confocal images reveal a high degree of
colocalization between huntingtin and the mitochondrial markers
cytochrome c and MitoRed. Bars = 10 μm.
Additional file 2: Figure S2. Cytosolic calcium levels in striatal cells.
A, representative confocal images of striatal cells loaded with Fluo3 AM.
Thapsigargin treatment induced an acute and transient calcium elevation
in both cell types. Bar =10 μm. B, representative trends of cytosolic
calcium levels in striatal cells treated with 1 μM thapsigargin during
30 min. Data correspond to the mean ± S.E.M. of 4 independent
experiments. C, quantitated data from 4 independent experiments of the
peak of cytosolic calcium levels observed in every condition indicated.
Data are mean ± S.E.M. * p < 0.05 compared with wild type cells treated
with 60 mM KCL; ** p < 0.05 compared with mutant cells treated with
60 mM KCL; # p < 0.05 compared with wild type cells treated with 1 nM
4-BrA23187 + 6 mM Ca2+; ## p < 0.05 compared with mutant cells treated
with 1 nM 4-BrA23187 + 6 mM Ca2+.
Additional file 3: Figure S3. Treatment with 4-BrA23187 + 6 mM Ca2+
affects mitochondrial health in mutant cells. A, representative confocal
images of striatal cells loaded with MitoRed to evaluate mitochondrial
potential changes in response to 1 nM 4-BrA23187 and 1 nM 4Br-A23187 +
6 mM Ca2+ treatment for 30 min. B, quantitated data of striatal cells
untreated and treated with 1 nM 4-BrA2387 + 6 mM Ca2+ and 1 nM
4-BrA23187 + 6 mM Ca2+ in the presence of 10 μM FCCP. Data are the
mean ± S.E.M. of 3 independent experiments. *, p < 0.05 compared with
wild type cells treated with 1 nM 4-BrA23187 + 6 mM Ca2+.
Additional file 4: Figure S4. Calcium stress induced oxidative stress in
mutant huntingtin expressing cells. A, representative trends of ROS levels
induced by the treatment with 100 μM H2O2 during 30 min. B,
representative trends of superoxide levels evaluated using MitoSOX/MTG
(see Methods for details) in striatal cells exposed to 1 μM thapsigargin for
30 min. C, ROS levels were evaluated with 2.7-DCF in wild type cells
exposed to 500 μM H2O2 for 30 min.
Additional file 5: Figure S5. Treatment with cyclosporine A prevents
cell viability loss in mutant huntingtin cells exposed to calcium overload.
A, representative images from striatal cells untreated and treated with 1
μM thapsigargin (Th), and 1 μM thapsigarin plus 0.5 μM cyclosporine A
(Th + CsA) for 24 h and loaded with calcein AM/Propidium Iodide (PI) to
evaluate cell viability loss. Cell death was estimated calculating the ratio
of fluorescence intensity between calcein (green) and PI (red) channels.
Bars represent 10 μm. B, quantification of calcein/PI ratio from
fluorescence images of 3 independent experiments. Thapsigargin
induced a significant decrease in cell viability in mutant cells. CsA
prevented cell viability loss induced by thapsigargin in mutant cells. Data
are the mean ± S.E.M. of 3 independent experiments. *, ** p < 0.05, using
Student’s t test.Additional file 6: Figure S6. Calcium stress induced mitochondrial
impairment in cortical neurons expressing mutant huntingtin. A, B, C,
representative confocal images of cortical neurons transfected with GFP,
Q25-GFP, and Q104-GFP and loaded with MitoRed to measure mitochondrial
potential changes in response to 1 μM thapsigargin. Treatment with
thapsigargin did not change mitochondrial potential in GFP and Q25-GFP
positive neurons (A, B). However, thapsigargin decreased mitochondrial
potential levels in Q104-GFP loaded cells (C). White arrows indicate Q25-GFP
and Q109-GFP expression in cortical neurons. Bar = 10 μm.
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